- $104.79m
- -$54.75m
- 41
- 46
- 93
- 63
Annual balance sheet for HilleVax, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 0.457 | 125 | 279 | 303 | 171 |
| Prepaid Expenses | |||||
| Total Current Assets | 0.505 | 125 | 291 | 311 | 178 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | — | 0.231 | 24.9 | 32.1 | 12.7 |
| Other Long Term Assets | |||||
| Total Assets | 0.505 | 127 | 317 | 344 | 193 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 3.28 | 228 | 13 | 29.3 | 16.5 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 3.28 | 228 | 50 | 78.9 | 38.2 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | -2.77 | -101 | 267 | 266 | 154 |
| Total Liabilities & Shareholders' Equity | 0.505 | 127 | 317 | 344 | 193 |
| Total Common Shares Outstanding |